← All trials
NCT05648500
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 13, 2022
- Primary completion
- Aug 31, 2025
- Completion date
- Feb 28, 2026
- First posted
- Dec 13, 2022
- Last posted
- Dec 23, 2022
- Enrollment
- 420
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Idorsia Pharmaceuticals Ltd.Lead sponsor
- Idorsia Pharmaceuticals Ltd.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.